Advertisement
New Zealand markets closed
  • NZX 50

    11,938.08
    +64.04 (+0.54%)
     
  • NZD/USD

    0.6012
    +0.0049 (+0.83%)
     
  • NZD/EUR

    0.5579
    +0.0023 (+0.42%)
     
  • ALL ORDS

    7,897.50
    +48.10 (+0.61%)
     
  • ASX 200

    7,629.00
    +42.00 (+0.55%)
     
  • OIL

    77.99
    -0.96 (-1.22%)
     
  • GOLD

    2,310.10
    +0.50 (+0.02%)
     
  • NASDAQ

    17,890.79
    +349.25 (+1.99%)
     
  • FTSE

    8,213.49
    +41.34 (+0.51%)
     
  • Dow Jones

    38,675.68
    +450.02 (+1.18%)
     
  • DAX

    18,001.60
    +105.10 (+0.59%)
     
  • Hang Seng

    18,475.92
    +268.79 (+1.48%)
     
  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     
  • NZD/JPY

    91.9390
    +0.3640 (+0.40%)
     

Coronavirus Disease 2019 (COVID-19) Clinical and Commercial Analyzer - August 2022

ReportLinker
ReportLinker

Summary The Coronavirus Disease 2019 (COVID-19) Clinical and Commercial Analyzer looks at the data from clinical trials for vaccines and therapeutics either currently marketed or in the pipeline.

New York, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Coronavirus Disease 2019 (COVID-19) Clinical and Commercial Analyzer - August 2022" - https://www.reportlinker.com/p06149521/?utm_source=GNW
The data is assessed, and the different products are compared against each other both clinically and commercially.

This report is an update of the previous COVID-19 Clinical and Commercial analyzer, which analyzes the available data of pipeline and marketed therapeutics and vaccines for COVID-19.

Report deliverables are an interactive Excel-based that has the Analyzer tab, which weights different clinical and commercial contributors per product, the competitive assessment tab, which is a graph representing the products by their clinical and commercial scores, the dashboard tab, which gives details and a SWOT analysis of each product, and the clinical data tab, which lists the key clinical trials and data for the products.

This update includes a weighted view of the impact of the Omicron variant on the products

Scope
- In depths assessment of the marketed and pipeline products for COVID-19, analyzing the clinical and commercial aspects of the products against one another.
- This update includes a weighted view of the impact of the Omicron variant on the products

Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of marketed and pipeline products and technologies, and by identifying the companies with the most robust pipeline and marketed products.
- Understand the strengths and weaknesses of pipeline and marketed products, and how they compare against one another.
- Develop business strategies by understanding the trends shaping and driving the COVID-19 market.
- Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global COVID-19 vaccine and therapeutic market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Read the full report: https://www.reportlinker.com/p06149521/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001